The most recent investor presentation from 20 september is a good place to start.
BD1 ovarian commercial assay is being developed as we speak. Due Q1 next year. Clinical trials are due to start at end of Q2 2019 CY with product launch estimated in 2021 (assuming all goes well).
I don't know how phases are defined but I'm guessing this means they're entering phase 2. So still a way to go yet.
The investor presentation also has a slide on competitors (slide 11).
The most recent investor presentation from 20 september is a...
Add IIQ (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
59.5¢ |
Change
0.005(0.85%) |
Mkt cap ! $65.61M | |||
| Open | High | Low | Value | Volume |
| 59.5¢ | 59.5¢ | 59.5¢ | $3.887K | 6.533K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 3467 | 59.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 60.0¢ | 5000 | 1 |
View Market Depth
| Last trade - 16.10pm 29/07/2024 (20 minute delay) ? |
| IIQ (ASX) Chart |